Medicus Pharma Announces $22 Million Non-Dilutive Financing
Rhea-AI Summary
Medicus Pharma (NASDAQ:MDCX) entered a definitive, non-dilutive structured financing facility of up to $22 million with an institutional investor. Medicus expects pro forma cash of about $30 million and a projected operating cash runway of more than 24 months.
The deal provides $12 million in immediate capital and $10 million in a milestone-based collateral account, via two secured promissory notes maturing in 18 months.
AI-generated analysis. Not financial advice.
Positive
- Up to $22 million non-dilutive structured financing facility
- Immediate operating capital of $12 million
- Additional $10 million in collateral account released on milestones
- Pro forma cash position expected at approximately $30 million
- Projected operating cash runway of more than 24 months
- Ability to optionally prepay notes subject to customary premiums
Negative
- Two secured promissory notes totaling $22.86 million issued
- Primary note carries 8.75% interest and 6.5% original issue discount
- Second note bears 5% interest, with funds in collateral account
- Notes are secured by substantially all company assets and subsidiary guarantees
- Financing includes an 18‑month maturity, concentrating repayment timeline
- Approximately $2.5 million of proceeds allocated to repay existing indebtedness
News Market Reaction – MDCX
On the day this news was published, MDCX gained 6.74%, reflecting a notable positive market reaction. Argus tracked a peak move of +38.1% during that session. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $21.97M at that time. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
MDCX gained 5.65% with two tracked peers (e.g., SCLX, AYTU) also moving up (median move about 11.3%). This points to both company-specific financing news and broader strength in the biotech/pharma segment.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 14 | Q1 earnings update | Negative | -10.7% | Quarterly results highlighted low cash, losses, and going-concern uncertainty. |
| May 06 | SkinJect Phase 2 data | Positive | +20.9% | Expanded Phase 2 SKNJCT-003 analysis showed strong dose-dependent efficacy and safety. |
| Apr 27 | Policy outreach | Positive | -5.7% | CEO met lawmakers seeking Orphan Drug and expedited regulatory pathways for SkinJect. |
| Apr 17 | Orphan Drug filing | Positive | +17.0% | Filed Orphan Drug Designation application with FDA for SkinJect in Gorlin Syndrome. |
| Apr 15 | Teverelix data update | Positive | -25.0% | Presented Phase 1 Teverelix data with hormone suppression but shares sold off sharply. |
Reactions to news have been mixed: positive clinical updates sometimes produced sharp gains, while earnings and corporate developments often saw selling pressure or divergence.
Over the last few months, Medicus reported multiple clinical and regulatory milestones for SkinJect and Teverelix. Positive Phase 2 SkinJect data and an Orphan Drug Designation application drove gains of 20.95% and 16.98%, respectively. However, Q1 2026 earnings on May 14 with going-concern language led to a -10.68% move, and Teverelix data shared on April 15 was followed by a -25.04% decline. Today’s non-dilutive financing strengthens liquidity against that backdrop of funding concerns.
Market Pulse Summary
The stock moved +6.7% in the session following this news. A strong positive reaction aligns with the announcement of an up to $22 million non-dilutive structured financing that lifts pro forma cash to about $30 million and extends runway beyond 24 months. Historically, funding concerns and going-concern language weighed on MDCX, so shoring up liquidity contrasts with prior risk flags. However, the stock still trades well below its $7.73 52-week high and below the $1.47 200-day MA, underscoring execution and debt-servicing risks.
Key Terms
secured promissory note financial
original issue discount financial
collateralized deposit account financial
orphan drug designation regulatory
expanded access ind program regulatory
generative ai technical
AI-generated analysis. Not financial advice.
Financing Provides Immediate Growth Capital to Support Clinical Development Initiatives and Extends Projected Operating Cash Runway for Over Two (2) Years
PHILADELPHIA, May 28, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced that it has entered into a definitive financing agreement with an institutional investor providing for an up to
The financing is expected to increase the Company’s pro forma cash position to approximately
Under the terms of the financing agreements, Medicus will receive
The financing consists of:
$12.86 million secured promissory note carrying an8.75% interest rate and a6.5% original issue discount; and$10 million secured promissory note carrying a5% interest rate with no original issue discount.
Maxim Group LLC is acting as the exclusive Placement Agent for the transaction.
“We believe this financing structure provides Medicus with meaningful capital flexibility while preserving the Company’s ability to support expanding strategic development initiatives,” stated Dr. Raza Bokhari, Medicus’ Executive Chairman and CEO. “This structure strengthens the Company’s financial outlook with nearly
The Company intends to use the net proceeds from the offering to support advancement of its current clinical development programs, potential strategic business development initiatives as well as for general corporate and working capital purposes, including the repayment of outstanding indebtedness of approximately
Under the terms of the financing, the notes are secured by substantially all Company assets and guaranteed by all of its subsidiaries.
The financing includes an 18-month maturity and permits optional early repayment by the Company subject to customary prepayment premiums.
For further details on the transaction, please refer to the Company’s Current Report on Form 8-K filing which is expected to be filed shortly with the U.S. Securities and Exchange Commission.
For further information contact:
Carolyn Bonner, President and Chief Financial Officer
(610) 636-0184
cbonner@medicuspharma.com
Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
adjokovic@medicuspharma.com
About Medicus Pharma Ltd.
Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision-guided biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries across three continents.
Company’s current key therapeutics assets are:
SkinJect™, a novel localized immuno-oncology precision product focused on non-melanoma skin diseases, especially basal cell carcinoma (BCC) and Gorlin Syndrome, a rare autosomal dominant disease also called nevoid BCC syndrome, collectively representing a ~
Teverelix®, a next generation GnRH antagonist is a first-in-market product for cardiovascular high-risk advanced prostate cancer patients and patients with acute urinary retention relapse (AURr) episodes due to enlarged prostate, collectively representing a ~
The Company is actively engaged in following collaborations:
SkinJect™ Platform Expansion
In August 2025, the Company announced its entry into a non-binding memorandum of understanding (MoU) with Helix Nanotechnologies, Inc. (HelixNano), a Boston-based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed, and there can be no assurance that such definitive agreements will be executed.
The Company is exploring co-development of thermostable infectious disease vaccines combining HelixNano’s proprietary mRNA technology with the Medicus microneedle array delivery platform.
Patient Access and Advocacy
In October 2025, the Company announced a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SkinJect™ for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome.
In collaboration with the Gorlin Syndrome Alliance, Medicus is pursuing an Expanded Access IND program to provide Gorlin Syndrome patients with multiple or inoperable BCCs access to SkinJect™, the Company’s investigational D-MNAs, under physician supervision.
AI Enabled Clinical Development
In December 2025, the Company signed a non-binding letter of intent to collaborate with Reliant AI Inc., a decision-intelligence company specializing in generative AI for the life sciences, to develop an AI-driven clinical data analytics platform to support capital-efficient and time-efficient clinical development through data-driven dynamic clinical-site selection, pharmacodynamic (PD) informed patient stratification, and enrollment forecasting. The initial phase of the collaboration is expected to support the upcoming Teverelix clinical study planned for 2026. There can be no assurance that a definitive agreement will be executed or that the proposed collaboration will proceed as contemplated.
Cautionary Notice on Forward-Looking Statements
Certain information in this news release constitutes “forward-looking information” under applicable securities laws. “Forward-looking information” is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the Company’s ability to continue as a going concern, statements regarding the Company’s leadership and prospects, the collaboration with GSA including the potential benefits thereof for GSA, those suffering with Gorlin Syndrome and Medicus (including as it relates to the development of SkinJect™), ability to be approved for the Registrational IND Program to enable those suffering with Gorlin Syndrome to access SkinJect™ under physician-supervised treatment protocols, Orphan drug designation for SkinJect™ the development of Teverelix and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix for AURr, high CV risk prostate cancer, women’s health indications like endometriosis, and the potential market opportunities related thereto, the MOU, including the potential signing of definitive agreements between Medicus and HelixNano and the development of thermostable infectious diseases vaccines by combining HelixNano’s proprietary mRNA vaccine platform with Medicus’s proprietary microneedle array (MNA) delivery platform, the Company’s aim to fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, including with respect to the Company’s submission for approval in the FDA Commissioner's National Priority Voucher program, plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of SkinJect™ through SKNJCT-003 and SKNJCT-004, and the potential market opportunities related thereto, the Company’s expectations regarding reported efficacy findings, the overall response rate and potential changes thereto, and whether there will be material changes to its reported SKNJCT-003 topline results and to secure an EOP2 meeting with the FDA in the first half of 2026, entry into definitive documents with Reliant and the expected terms thereof, engaging in proposed Medicus-sponsored studies currently contemplated in the Reliant non-binding letter of intent and the expected benefits thereof, the expansion of SKNJCT-003 into the United Kingdom and the potential benefits therefrom, the advancement of the SKNJCT-004 study and the potential results of and benefits of such study, the Company’s ability to raise capital in future debt and equity offerings and the sufficiency of such financing infrastructure to support ongoing and future operations and advancement of its clinical development programs, the Company's expectations regarding the structured financing facility, including the Company's ability to achieve specified balance reduction milestones thereunder, the Company’s anticipated use of proceeds and the Company's expectations regarding its cash position and financial outlook following the closing of the financing, and the potential expansion of strategic collaborations and licensing. Forward-looking statements are often but not always, identified by the use of such terms as “may”, “on track”, “aim”, “might”, “will”, “will likely result”, “could”, “designed”, “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target”, “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's annual report on form 10-K for the year ended December 31, 2025, and in the Company's other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
